Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Roche Opting Out, ArQule Uncertain On Plans For E2F Oncology Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Well-capitalized biotech had planned to launch Phase I investigation of E2F molecule in 2009 before Roche’s unexpected decision.

You may also be interested in...

ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo

Two deals bring the biotech $75 million upfront, plus research and clinical development funding.

Let The Negotiations Begin: Genentech Rejects Roche’s $44 Billion Bid

Genentech’s announcement that Roche’s $89 per share bid undervalues the biotech comes as little surprise. But how much is Roche willing to pay?

Pandemic Puts A Spotlight On Counterfeit Drugs

As the ongoing COVID-19 pandemic forces health care to go digital, opportunities for fraud have proliferated. In Vivo explores the risks, the steps regulators are taking and how companies are looking to provide innovative solutions to help secure manufacturing supply chains.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts